Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,405.20
(
-2.38%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.89
(
0.00%
)
Bitcoin
66,806.87
(
0.70%
)
News Focus
News Focus
Post# of 257301
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122817
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 216870

Friday, 02/02/2018 8:24:07 AM

Friday, February 02, 2018 8:24:07 AM

Post# of 257301
Re: ABBV/ENTA US HCV scripts/week ending 1/26/18 (IMS)

ABBV/ENTA’s new-patient share (NRx) reached 35.6%, the highest-ever level reported by IMS. (Almost all of ABBV/ENTA’s US patient share is now coming from Mavyret.) ABBV/ENTA’s total-patient share (TRx) reached 29.3%.

The actual Mavyret figures reported by IMS for the week ending 1/26/18 are:

NRx 951 (+21% vs prior week)
TRx 1607 (+17% vs prior week)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now